APA (7th ed.) Citation

T, Z., IA, M., R, W., P, H., DM, S., A, H., & C, K. (2023). Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Frontiers in immunology, 14, 1240275. https://doi.org/10.3389/fimmu.2023.1240275

Chicago Style (17th ed.) Citation

T, Zeller, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, and Kellner C. "Perspectives of Targeting LILRB1 in Innate and Adaptive Immune Checkpoint Therapy of Cancer." Frontiers in Immunology 14 (2023): 1240275. https://doi.org/10.3389/fimmu.2023.1240275.

MLA (9th ed.) Citation

T, Zeller, et al. "Perspectives of Targeting LILRB1 in Innate and Adaptive Immune Checkpoint Therapy of Cancer." Frontiers in Immunology, vol. 14, 2023, p. 1240275, https://doi.org/10.3389/fimmu.2023.1240275.